All News

gout.bigtoe1.jpg (keep)

Four Lifestyle Changes to Prevent Gout

MedPage Today

JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men.

Read Article
cost.healthcare.jpg

Colchicine Approval Took a Huge Toll on CMS

Colchicine, the old gout drug often cited as a cheap anti-inflammatory, hasn't been such a good deal since FDA approval, a study in JAMA Internal Medicine showed.

Read Article
gout.podagra.jpg

Pegloticase in Severe Refractory Gout

Olga Petryna, MD

Listen as Dr. Petryna reviews abstracts #0683 (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate) and #0677 (A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study) from the 2020 ACR meeting. 

Read Article
Content Download Available! Download our document on arthritis myths below. https://t.co/2Kxpou4Fbz https://t.co/iPIqR92ME1

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR20 Mid Meeting Recap: Gout https://t.co/MhaYjotrmb https://t.co/R4dOrSlFl6

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiovascular Safety for Feboxustat with Dr. Nicola Dalbeth examines the cardiovascular safety in the FAST trial of Feboxustat at #ACR20. https://t.co/XCdtWpLKWR https://t.co/BLQdK6tq2s

Links:

Dr. John Cush RheumNow ( View Tweet)
Early view in ACR Open Access: Patient Perspectives on Gout and Gout Treatments: A Patient Panel Discussion That Informed the 2020 American College of Rheumatology Treatment Guideline https://t.co/QY6pofhamT

Links:

ACR_Journals ACR_Journals ( View Tweet)

Four Lifestyle Changes to Prevent Gout JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men. Read more below. https://t.co/6eYA75TjPx https://t.co/kLG9ANCxB9

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Ken Saag -- RECIPE Study: MMF with Pegloticase Dr. Jack Cush interviews Dr. Ken Saag about the benefits of adding mycophenolate to your pegloticase regimen in refractory gout patients. #acr20 https://t.co/lpDuahgiVa https://t.co/nb8TqwKP5W

Links:

Dr. John Cush RheumNow ( View Tweet)
Important Gout cohort study of 44 654 US men followed x 26 yrs, shows that 77% of incident gout would have been prevented with thes 4 modifiable risk factors: 1) normal weight, 2) adhere to DASH diet, 3) no alcohol, & 4) no diuretics https://t.co/UsDAN8OykX https://t.co/ivBTb8Nyfw

Links:

Dr. John Cush RheumNow ( View Tweet)
What's New in Calcium Pyrophosphate Disease? NYU's Dr. Michael Pillinger discusses about Dr. Ann Rosenthal's state of the art talk on calcium pyrophosphate disease at #ACR20. https://t.co/UDxku4xK0C https://t.co/J661yvO06S

Links:

Dr. John Cush RheumNow ( View Tweet)
Febuxostat bad for the heart? Not so FAST: Dr. Jeffrey Curtis ( @RADoctor) #ACR20 https://t.co/8YFjGslJ7E

Links:

Dr. John Cush RheumNow ( View Tweet)

Comorbidities in Gout with Dr. Nicola Dalbeth https://t.co/RfXfk1MnWj https://t.co/X01lbf5fm7

Links:

Dr. John Cush RheumNow ( View Tweet)
Pipeline Therapies for Urate Lowering: Dr. Michael Pillinger #ACR20 https://t.co/M3ahjjZWK8 https://t.co/Ipc0nowK2t

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/EUXQqy3VuI
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @DrPetryna : #ACR20 Abs L08 Prosp. 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat not associated w/increased risk of death compared w/allopurinol.7.2% pts died in the febuxostat group compared to 8.6% in the allopurinol group

Dr. John Cush RheumNow ( View Tweet)

Listen as Dr. Petryna ( @DrPetryna) reviews several pegloticase-related abstracts presented at the #ACR20 meeting. https://t.co/TBi1uRPXG0 https://t.co/wAUNr4mq1v

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @Janetbirdope : Gout has more comorbidities than RA & PsA #1466 Half of respondents are correct @RheumNow @CRASCRRheum #ACR20 https://t.co/T81eo3CGjq

Links:

Dr. John Cush RheumNow ( View Tweet)

Auckland-based rheumatologist Dr. Nicola Dalbeth discusses improving responses to the use of Pegloticase, including abstracts #0677 and #0952 presented at #ACR20. https://t.co/xeiMYLZEQa https://t.co/a4RJ6BrNgn

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×